Health-care resource utilisation and cost one year after hospitalisation among patients hospitalised with viral lower respiratory tract disease: A descriptive US claims analysis

<bold>Background:</bold> The disease burden associated with severe viral lower respiratory tract disease (LRTD) can be substantial in the acute setting but can also persist long after hospitalisation. <bold>Aims:</bold> To describe long-term health-care resource utilisation (HCRU) and related costs in US adult patients hospitalised with viral LRTD who survived one year after hospitalisation. <bold>Methods:</bold> HCRU and related costs in patients hospitalised with viral LRTD during 2022 were analysed using Optum’s de-identified Clinformatics^® Data Mart database in the one year after hospitalisation compared with the year before. <bold>Results:</bold> The mean (SD) age in the overall cohort (N=22,632) was 72 (14) y. The average number of total visits and the average cost per patient in the one year after hospitalisation were 66 and $52,413, respectively. Compared with the one year before hospitalization, the number of total visits increased by 27% and total costs increased by 42%. The increases in number of total visits and total costs were highest (88% and 112%, respectively) in patients who received IMV/ECMO (Figure). <bold>Conclusions:</bold> Among those hospitalised for viral LRTD, HCRU and costs substantially increased up to one year after hospitalisation compared with the year before, especially in patients who received IMV/ECMO, creating a significant long-term burden for health-care systems. <fig><object-id>erj;64/suppl_68/PA3290/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>